BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 33677764)

  • 1. Optimal Timing of Initiating Dynamic Risk Stratification During the Early Postoperative Period in Patients with Differentiated Thyroid Carcinoma After Thyroidectomy and Radioactive Iodine Remnant Ablation.
    Park JH; Moon GS; Nam KT; Yoon JH
    Ann Surg Oncol; 2021 Oct; 28(11):6580-6589. PubMed ID: 33677764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the abilities of staging and risk stratification systems to predict the long-term structural recurrence in patients with differentiated thyroid carcinoma after total thyroidectomy and radioactive iodine remnant ablation.
    Nam KT; Park JH; Moon GS; Yoon JH
    Gland Surg; 2021 Jul; 10(7):2200-2210. PubMed ID: 34422591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamic Risk Stratification for Predicting Recurrence in Patients with Differentiated Thyroid Cancer Treated Without Radioactive Iodine Remnant Ablation Therapy.
    Park S; Kim WG; Song E; Oh HS; Kim M; Kwon H; Jeon MJ; Kim TY; Shong YK; Kim WB
    Thyroid; 2017 Apr; 27(4):524-530. PubMed ID: 27869547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Superiority of delayed risk stratification in differentiated thyroid cancer after total thyroidectomy and radioactive iodine ablation.
    Hong CM; Lee WK; Jeong SY; Lee SW; Ahn BC; Lee J
    Nucl Med Commun; 2014 Nov; 35(11):1119-26. PubMed ID: 25144561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Follow-Up Strategy for Patients with an Excellent Response to Initial Therapy for Differentiated Thyroid Carcinoma: Less Is Better.
    Jeon MJ; Kim M; Park S; Oh HS; Kim TY; Kim WB; Shong YK; Kim WG
    Thyroid; 2018 Feb; 28(2):187-192. PubMed ID: 29179642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Timing of Radioactive Iodine Administration Does Not Influence Outcomes in Patients with Differentiated Thyroid Carcinoma.
    Scheffel RS; Zanella AB; Dora JM; Maia AL
    Thyroid; 2016 Nov; 26(11):1623-1629. PubMed ID: 27549175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of the impact of 2015 American Thyroid Association guidelines in management of differentiated thyroid cancer patients.
    Choudhury S; Agrawal A; Pantvaidya G; Shah S; Purandare N; Puranik A; Rangarajan V
    Eur J Nucl Med Mol Imaging; 2020 Mar; 47(3):547-553. PubMed ID: 31707429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamic Risk Estimates of Outcome in Chinese Patients with Well-Differentiated Thyroid Cancer After Total Thyroidectomy and Radioactive Iodine Remnant Ablation.
    Shen FC; Hsieh CJ; Huang IC; Chang YH; Wang PW
    Thyroid; 2017 Apr; 27(4):531-536. PubMed ID: 28007013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Age, thyroglobulin levels and ATA risk stratification predict 10-year survival rate of differentiated thyroid cancer patients.
    Kelly A; Barres B; Kwiatkowski F; Batisse-Lignier M; Aubert B; Valla C; Somda F; Cachin F; Tauveron I; Maqdasy S
    PLoS One; 2019; 14(8):e0221298. PubMed ID: 31425569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radioiodine Remnant Ablation for Differentiated Thyroid Cancer: A Systematic Review and Meta-analysis.
    James DL; Ryan ÉJ; Davey MG; Quinn AJ; Heath DP; Garry SJ; Boland MR; Young O; Lowery AJ; Kerin MJ
    JAMA Otolaryngol Head Neck Surg; 2021 Jun; 147(6):544-552. PubMed ID: 33792650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modified dynamic risk stratification for predicting recurrence using the response to initial therapy in patients with differentiated thyroid carcinoma.
    Jeon MJ; Kim WG; Park WR; Han JM; Kim TY; Song DE; Chung KW; Ryu JS; Hong SJ; Shong YK; Kim WB
    Eur J Endocrinol; 2014 Jan; 170(1):23-30. PubMed ID: 24088549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of radioactive iodine treatment on survival among papillary thyroid cancer patients according to the 7th and 8th editions of the AJCC/TNM staging system: a SEER-based study.
    Liu X; Fan Y; Liu Y; He X; Zheng X; Tan J; Jia Q; Meng Z
    Updates Surg; 2020 Sep; 72(3):871-884. PubMed ID: 32342347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dynamic Risk Stratification for Predicting Long-term Outcomes in Pediatric Differentiated Thyroid Cancers.
    Majeed AK; Satapathy S; Ballal S; Bal C
    J Clin Endocrinol Metab; 2023 May; 108(6):e208-e215. PubMed ID: 36577747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system.
    Tuttle RM; Tala H; Shah J; Leboeuf R; Ghossein R; Gonen M; Brokhin M; Omry G; Fagin JA; Shaha A
    Thyroid; 2010 Dec; 20(12):1341-9. PubMed ID: 21034228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients.
    Castagna MG; Maino F; Cipri C; Belardini V; Theodoropoulou A; Cevenini G; Pacini F
    Eur J Endocrinol; 2011 Sep; 165(3):441-6. PubMed ID: 21750043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intermediate-Risk Papillary Thyroid Cancer: Risk Factors for Early Recurrence in Patients with Excellent Response to Initial Therapy.
    Llamas-Olier AE; Cuéllar DI; Buitrago G
    Thyroid; 2018 Oct; 28(10):1311-1317. PubMed ID: 30105948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of early vs late postoperative radioiodine remnant ablation on final outcome in patients with low-risk well-differentiated thyroid cancer.
    Tsirona S; Vlassopoulou V; Tzanela M; Rondogianni P; Ioannidis G; Vassilopoulos C; Botoula E; Trivizas P; Datseris I; Tsagarakis S
    Clin Endocrinol (Oxf); 2014 Mar; 80(3):459-63. PubMed ID: 23895145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ongoing risk stratification for differentiated thyroid cancer (DTC) - stimulated serum thyroglobulin (Tg) before radioiodine (RAI) ablation, the most potent risk factor of cancer recurrence in M0 patients.
    Krajewska J; Jarząb M; Czarniecka A; Roskosz J; Kukulska A; Handkiewicz-Junak D; Puch Z; Wygoda Z; Paliczka-Cieślik E; Kropińska A; Gubała E; Jurecka-Lubieniecka B; Jarząb B
    Endokrynol Pol; 2016; 67(1):2-11. PubMed ID: 26884109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radioactive iodine (RAI) therapy for distantly metastatic differentiated thyroid cancer (DTC) in juvenile versus adult patients.
    Kammori M; Fukumori T; Sugishita Y; Hoshi M; Shimizu K; Yamada T
    Endocr J; 2015; 62(12):1067-75. PubMed ID: 26424174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dynamic risk stratification for predicting the recurrence in differentiated thyroid cancer.
    Ozkan E; Soydal C; Nak D; Kucuk NO; Kir KM
    Nucl Med Commun; 2017 Dec; 38(12):1055-1059. PubMed ID: 28957841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.